EGFR and non-small cell lung carcinoma: Among them, single-agent osimertinib has become the primary choice for first-line treatment of EGFR-mutated advanced NSCLC on the basis of the results of a randomized phase 3 trial in which prolonged progression-free survival (PFS) and overall survival (OS) were achieved with osimertinib treatment compared with that observed with gefitinib or erlotinib treatment (median PFS, 18.9 versus 10.2 mo; hazard ratio [HR] = 0.46 [95% confidence interval (CI): 0.37–0.57]).11